A prespecified analysis of 270 IgAN patients enrolled in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Trial revealed a hazard ratio of 0.29 (95% CI 0.12–0.73) for the primary end-point (50% decline in eGFR, ESKD, death from kidney or cardiovascular causes), a 26% reduction in albumin/creatinine ratio, and a lower rate of eGFR decline (137). This evidence concerns the gene ALB and chronic kidney disease.